FRA:MRKMerck KGaA Stock Price, Forecast & News

€103.15

-1.35 (-1.29 %)

(As of 06/1/2020 11:48 AM ET)

Add

Compare

Today's Range

€103.00

Now: €103.15▼

€104.90

50-Day Range

€95.80

MA: €103.22▼

€107.95

52-Week Range

€76.60

Now: €103.15▼

€115.00

Volume745,010 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Beat the Market (BTM) Rank^™

2.1 Analyst's Opinion

Consensus Rating
Merck KGaA has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 4 buy ratings, 9 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of €108.36, Merck KGaA has a potential upside of 5.0% from its current price of €103.15.
Amount of Analyst Coverage
Merck KGaA has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.3 Community Rank

Outperform Votes
Merck KGaA has received 824 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Merck KGaA has received 960 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Merck KGaA has received 53.81% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote “Outperform” if you believe MRK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Merck KGaA does not currently pay a dividend.
Dividend Growth
Merck KGaA does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck KGaA insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.87 out of 5 stars

Industry, Sector and Symbol

Stock Exchange FRA

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolFRA:MRK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.merckgroup.com

Phone+49-6151-720

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees51,039

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableOptionable

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Merck KGaA (FRA:MRK) Frequently Asked Questions

How has Merck KGaA's stock been impacted by COVID-19 (Coronavirus)?

Merck KGaA's stock was trading at €98.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK stock has increased by 4.5% and is now trading at €103.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Merck KGaA?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 2 sell ratings, 9 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Merck KGaA.

What price target have analysts set for MRK?

15 brokerages have issued 1 year price targets for Merck KGaA's shares. Their forecasts range from €90.00 to €125.00. On average, they anticipate Merck KGaA's share price to reach €108.36 in the next twelve months. This suggests a possible upside of 5.0% from the stock's current price. View analysts' price targets for Merck KGaA.

Has Merck KGaA been receiving favorable news coverage?

Media coverage about MRK stock has been trending somewhat positive recently, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Merck KGaA earned a news impact score of 1.0 on InfoTrie's scale. They also assigned news articles about the healthcare company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutMerck KGaA.

Who are some of Merck KGaA's key competitors?

Some companies that are related to Merck KGaA include 1933 Industries (TGIF), Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Biome Grow (BIO), Blueberries Medical (BBM), Canbiola (CANB), Cannabis Science (CBIS), Cannara Biotech (LOVE), Cansortium (CNTMF), Charlotte's Web (CWBHF), Choom (CHOOF) and Cipher Pharmaceuticals (CPHRF). View all competitors.

What other stocks do shareholders of Merck KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck KGaA investors own include Micron Technology (MU), Abbott Laboratories (ABT), Cisco Systems (CSCO), NVIDIA (NVDA), Boeing (BA), Pluristem Therapeutics (PSTI), QUALCOMM (QCOM), HDFC Bank (HDB), IBM (IBM) and Johnson & Johnson (JNJ).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the following people:

Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €103.15.

What is Merck KGaA's official website?

The official website for Merck KGaA is www.merckgroup.com.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.

This page was last updated on 6/1/2020 by MarketBeat.com Staff

FRA:MRKMerck KGaA Stock Price, Forecast & News

Adding

Adding

Adding Merck KGaA

Beat the Market (BTM) Rank™